Rong Zhou Sells 3,187 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock

Posted by Geri Gentry on Sep 5th, 2026

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Free Report) EVP Rong Zhou sold 3,187 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $23.63, for a total transaction of $75,308.81. Following the sale, the executive vice president owned 169,203 shares in the company, valued at approximately $3,998,266.89. This trade represents a 1.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Amphastar Pharmaceuticals Trading Down 2.8%

Shares of AMPH opened at $23.18 on Friday. The stock has a fifty day moving average of $20.51 and a two-hundred day moving average of $20.61. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.71 and a current ratio of 2.40. The company has a market capitalization of $986.03 million, a PE ratio of 13.72, a price-to-earnings-growth ratio of 4.59 and a beta of 0.92. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $16.65 and a fifty-two week high of $29.78.

Amphastar Pharmaceuticals (NASDAQ:AMPH – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.29. The company had revenue of $183.90 million for the quarter, compared to analyst estimates of $179.92 million. Amphastar Pharmaceuticals had a return on equity of 14.98% and a net margin of 10.76%. As a group, analysts forecast that Amphastar Pharmaceuticals, Inc. will post 2.46 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Wells Fargo & Company boosted their price objective on shares of Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, July 8th. Piper Sandler reduced their target price on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating on the stock in a report on Friday, August 7th. Bank of America reissued an “underperform” rating and set a $20.00 price target (down from $25.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, June 29th. Finally, Zacks Research upgraded Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 21st. Six research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Amphastar Pharmaceuticals presently has a consensus rating of “Reduce” and an average price target of $22.50.

View Our Latest Analysis on AMPH

Hedge Funds Weigh In On Amphastar Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Quarry LP acquired a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter valued at $32,000. Farther Finance Advisors LLC increased its holdings in Amphastar Pharmaceuticals by 46.3% in the 4th quarter. Farther Finance Advisors LLC now owns 1,381 shares of the company’s stock valued at $37,000 after purchasing an additional 437 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Amphastar Pharmaceuticals in the 2nd quarter valued at $39,000. TD Private Client Wealth LLC raised its position in Amphastar Pharmaceuticals by 410.1% in the fourth quarter. TD Private Client Wealth LLC now owns 2,418 shares of the company’s stock valued at $65,000 after purchasing an additional 1,944 shares during the period. Finally, Tower Research Capital LLC TRC raised its position in Amphastar Pharmaceuticals by 263.0% in the second quarter. Tower Research Capital LLC TRC now owns 3,583 shares of the company’s stock valued at $82,000 after purchasing an additional 2,596 shares during the period. Hedge funds and other institutional investors own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

(Get Free Report)

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.